Newest Issue is Out. Get your exclusive copy today.
The COVID pandemic has impacted many industries alike and the impact on biosimilars market was no different Lockdowns causing short fall of resources delays in clinical trials slowdown in FDA approvals of nonCOVID drugs have influenced the RD activities and the biosimilars pipeline
In April this year three companiesUS real estate investment company Harrison Street UK real estate group Trinity Investment Management and Nottinghambased science business incubator BioCitymerged to create Britains largest life sciences ecosystem to strengthen RD and drug discovery in the country
In recent years precision medicine has emerged as a promising tool for providing patients suffering from complex diseases with comprehensive care Whether it is traumatic cancer cardiac disease lung disorder or COVID for that matter the precision medicine approach has proved to be very effective in improving patients health or reduction of disease s...
Across the world one thing that has been a hot topic since the pandemic started is the arrival of a COVID vaccine COVID led several pharma companies to pursue vaccine production with aggressive deadlines and a sense of urgency in developing and bringing to market
We live in the digital era but one would have never imagined a world with little or significantly lesser inperson interaction COVID has consumed numerous lives crippled economies and left millions in distress
The COVID pandemic hit industries across the globe as countries adopted various measures that included travel restrictions border closures to imposing nationwide lockdown in a bid to contain or slowdown the spread of virus Almost six months after the novel corona virus was first diagnosed in China the number of patients currently standing at milli...
Clinical trials are imperative for testing drugs and therapies advancing the science of care and coming up with an effective treatment approach to enhance outcomes for patients
The pharmaceutical industry has for several decades been reliant on batch manufacturing which dominated the blockbuster drug era
An estimated million people use connected wearable devices according to IMARC
Who would have imagined internetconnected medicine to be a reality until the FDA approved schizophrenia pill came into the market in late
In the digital age where technology is leading the way blockchain has emerged as a disruptor in several industries from financial services to energy and life sciences Blockchain allows visibility and data integrity along with security against data hacking through decentralised blocks linked by the cryptography technique The pharma industry has f...
In recent years Chinas investment in drug innovation has been on the rise The countrys pharmaceutical market is second only to the US at approximately US billion as of and is expected to increase at a CAGR of per cent to US billion by Interestingly China has become the leader in API manufacturing and exports Historically the pharmaceutical marke...
Despite years of efforts drug development continues to be challenging complex costintensive and timeconsuming The pharma RD process requires years of research and huge data gathering Through the whole process from discovery and development to clinical trial a drug developer would have gathered massive data on compounds diseases patient information...
Continuous screening provides employers with a valuable tool to best evaluate their risks and ensure they place their employees in the most appropriate positions Lucia Bone Performing background verification or screening of new hires has been a practice the world over to ensure the organisation employs individuals that are talented and skilful a...
If we hope to create something of lasting value we need to start with what people want not just with whats technically possible IDEO a global design firm Innovation and technology advancements play a key role in product design and development but it is imperative that companies bring in a humancentred approach The advent of new technologies suc...
Modelling Simulation in Drug DevelopmentPharma companies look to improve experimental drug success rate and accelerate clinical development while striving to improve efficiency costeffectively It is imperative for companies to be cautious in decision making to increase the probability of commercial success for developing the drug Major pharmaceuti...
Pharma industry has witnessed a staggering decline in RD productivity and is now a major cause of concern for the industry players This decline contributed to a downfall in the return on investments over the last two decades Interestingly there has been a trend reversal with increase in clinical trial success rate and drug development during Incre...
From initiation to marketing of the drug compounds face numerous challenges to become an approved drug Apart from preclinical financial and approval stages successful recruitment of patients for conducting clinical trials is one of the most challenging aspects Factors like lack of patient education about clinical trials and complex study designs ar...
Translational Medicine TM has redefined Pharma RD It has broken down the silos that existed between research drug development and clinical medicine and as a result presented a great promise At a time when the industry is struggling to keep up with rising costs thinning pipe lines and a high failure rate for drugs during trials a process like TM poi...
Pharmaceutical regulators are becoming more cautious about approving innovative medicines for consumers safety The US Food and Drug Administration FDA has established many regulations that govern the development testing and production processes of drugs As part of streamlining these processes and addressing the cost trends FDASIA FDA Safety and Inn...
Pharmaceutical companies operate in one of the most dynamic environments Changes in regulations by leading bodies such as US Food and Drug Administration USFDA and the European Medicines Agency EMA have increased the significance of regulatory compliance management for drug manufacturers Pharma companies across the globe are compelled to alter thei...
As they target new types of diseases in specialistareas such as oncology and diabetes thepharma companies are investing in innovativetreatments to address these unmet clinicalneeds According to IMS health in the amountspent on innovating new medicines is more thatthe amount spent on brands associated withnew generic entrants The global
Bacterial resistance is developing quickly and many critically important drugs risk becoming obsolete warned the World Health Organization WHO in April Antimicrobial resistance AMR has emerged as a major threat for public health worldwide owing to ineffective use of antibiotics due to increasing patients demand
The golden era of blockbuster drugs is coming to an end but there are reasons to believe that new growth opportunities exist for pharma companies willing to adapt to the change The FDA approved New Molecular Entities NME in and this number came down from in and in Twentyeight firstofakind drugs were approved annually over the past five
New tools and innovative developments in technology have played a key role in the field of medicine One such technology that is enabling great amount of efficiencies in pharmaceutical development is mobile phones This technology which has revolutionised sharing of information digitally has wide applications in the pharmaceutical industry
Investments in nanotechnology by governments and industries have been accelerating at a good pace globally However the pharmaceutical industry has been slow in investing and adopting the technology With the failure of the blockbuster model dwindling revenues pressure from generics patent losses declining product pipelines and ever rising RD cost...
While mergers and acquisitions partnerships and collaborations still offer avenues for growth for the pharma industry many feel that the concept of personalised medicine if used intelligently will set the industry on the right path By enabling highlycustomised therapies to treat diseases based on the patients genetic makeup personalised medicine...
The global pharmaceutical industry today is severely affected by a combination of adverse factors fast depleting new drugs in the pipeline mounting costs of developing new drugs patent expiries of many a blockbuster of yesteryears intense competition from generics threat of counterfeits etc The tale of its woes is indeed endless
The era of generics is all set to hit the biotech industry Not so long back the fledgling industry for biosimilars was threatening to not take off due to the lack of proper ground work of regulations But the strengthening regulatory framework for biosimilars especially in Europewith USA expected to follow suitmight have given biosimilars a fresh
Rationale for pharma biobanking Despite significant advances there is still need for better highly effective and welltolerated therapies for many indications This requires the collaboration of scientists clinicians and basic researchers from academic as well as industrial research It is practically impossible to generate new kn
According to a Prospective Pilot Cohort study that was conducted for a week period in patients out of a total of were identified as having possible DILI and of these accepted to be included in the protocol During the oneweek proactive period seven patients out of a total of inpatients were identified with possible DILI
After more than a decade of showing disinterest the pharma industry is taking a relook at natural productsbased drug discovery Pharma companies had shifted their focus from natural products to combinatorial chemistry because of lower costs clarity on intellectual property and importantly because it could supply huge synthetic libraries in short per...
The pharma industry today operates in an uncertain environment Intensifying cost pressures declining revenue streams increasing latestage failures stringent price controls and an uncertain global economy add to its woes In the rapidly changing pharma landscape w
Contamination of drugs during manufacturing is not a new phenomenon In todays global manufacturing landscape it becomes even more imperative the manufacturers have processes in place to mitigate the risk of contamination Nevertheless drug contamination has emerged as a leading cause of recalls lately According to the Medici
Asias clout in global clinical trials with these growth regions is expected to continue growing in the coming decade Global CROs are expanding their presence in Asia in line with market growth Given this potential the number of studies in the region has increased significantly and approvals have followed suit According to
Welcome to the latest edition of Pharma Focus Asia The issue of outsourcing in the pharmaceutical sector has been a hot topic for discussion recently particularly now that the US Congress is considering reforming patent law The new legislation could have significant repercussions for firms that use the USA as part of their business strategy especia...
These are tough days for worlds Big Pharma Depleting pipelines patent expirations soaring RD costs and risks etc have all put the Big Pharma in rough weather Against this backdrop fast growing Asian economies notably China and India represent new horizons of opportunities The silver lining to this gloomy scenario is the fast transforming Indian ph...
Multinational companies are looking eastward in their endeavor to create new therapeutics by partnering with emerging pharma companies from China India and other south east Asian economies Big pharma companies are also investing in large scale RD facilities a recent example of this being Novartis announcement to invest US billion in a RD facility i
Changing patterns of diseases ageing population price controls dry RD pipelines patent expirations for many blockbuster drugs and declining global generic market opportunities are a wakeup call for pharma Moreover the shift in focus to improved outcomes is pushing pharma companies to rethink on the existing business models for more productive RD so...
The pharma industry is treading a new path for sustaining growthpartnerships Escalating RD costs tough regulations and price controls continue to trouble the industry Further a severe blockbuster drought patent expiries and anaemic drug pipelines have only added to the industrys woes Innovation did provide hope but even that has become a high
The key to the success of a drug development programme is the effective management of clinical trials Clinical trials today are bigger more complex spread across multiple sites and conducted in evershrinking timelines making their management a daunting task However optimal management of Clinical Trials Supply Chain could play an important role in c...
